Evidence map›Paper›PMID 40979481›Full record

ArticleJournal of traditional and complementary medicine2025

Nao-Xin-Qing tablet inhibits macrophage inflammatory response in atherosclerosis via AMPK-α/SIRT1/PPAR-γ pathway.

Guiting Zhou, Chenxi Wang, Zhichao Lin, Liwen Lin, Ruochen Zhu, Shushu Wang, Jiongbo Xu, Yuxin Xie, Yuling Zhang, Danling Cheng and 5 more

Abstract read
In one paragraph

Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guiting ZhouDepartment of Cardiology, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
Chenxi WangYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhichao LinFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Liwen LinFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ruochen ZhuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shushu WangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jiongbo XuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuxin XieFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuling ZhangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Danling ChengFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chun ZhouSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Juan LinHutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd, Guangzhou, China.
Haibiao GuoHutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd, Guangzhou, China.
Min LiuHutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd, Guangzhou, China.
Chuanjin LuoFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Nao-Xin-Qing (NXQ) tablets are standardized proprietary herbal products containing an extract of Chinese persimmon leaves ( Experimental procedure: In vivo, the apolipoprotein E-deficient (ApoE Results: In our study, we found that NXQ significantly reduced atherosclerotic plaques in the aortic root and aorta and decreased serum lipid levels in HFD-fed ApoE Conclusion: NXQ exerted a preventive effect on the development and progression of AS by promoting M2 macrophage polarization through modulation of the AMPK-α/SIRT1/PPAR-γ axis.

Indexed as

AMPK-αApoE−/− miceAtherosclerosisMacrophage polarizationNao-Xin-Qing tablets

Identifiers

PMID40979481
PMCPMC12447142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.